SCIENTIFIC BACKGROUND

PAH

Autosomal recessive phenylketonuria (PKU) is the most common genetic disorder of amino acid metabolism (prevalence 1:7,500-8,500). Due to a defect in phenylalanine hydroxylase (PAH), the amino acid phenylalanine can no longer be sufficiently metabolized to tyrosine. This leads to an unphysiological accumulation of phenylalanine, which, if left untreated, results in pronounced brain damage and consequently, severe psychomotor retardation. The molecular cause is found in pathogenic variants in the PAH gene, which codes for phenylalanine hydroxylase. Numerous variants have been described that lead either to reduced enzyme activity or to complete failure of the enzyme. This also explains the existing genotype-phenotype correlation. The combination of two "mild variants" or a "mild" with a "severe variant" usually leads to mild hyperphenylalaninemia or mild phenylketonuria, respectively. The combination of two "severe variants" predominantly leads to classic phenylketonuria. However, this genotype-phenotype correlation is not always present, and variants have been described that can lead to different phenotypes when present in homozygous form.

 

Treatment of PKU is a strict low phenylalanine diet. Another treatment option is the administration of tetrahydrobiopterin (BH4), a cofactor of phenylalanine hydroxylase. In pharmacological doses, tetrahydrobiopterin is able to stabilize the structure of misfolded phenylalanine hydroxylase (molecular chaperone) and increase its enzyme activity. A large proportion of patients benefit from BH4 therapy. There are also genotype-phenotype correlations in the efficacy of BH4 therapy, which in many cases allow the response to therapy to be estimated in advance.

 

Diagnosis of phenylketonuria is part of newborn screening. In the case of abnormal findings, the diagnosis can be confirmed by molecular genetics. With timely initiation of therapy and adherence to the necessary dietary measures, the disease is readily treatable.

 

References
Regier and Greene CL  2000 [Updated 2017 Jan 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019 / Blau 2016 Hum Mutat. ;37(6):508-15 / Zurflüh et al. 2008, Hum Mutat 29:167

GENES

PAH

ASSOCIATED TESTS

How to order

LATEST ARTICLES

Cancer is a group of genetic diseases that can develop almost anywhere in the body. Many people in the world are affected by cancer every year. Follo...

Read more

Aiming to evaluate the role of chromosomal aneuploidy in pregnancy loss, a 2023 study 35 years in the making evaluated the genomic landscape of first...

Read more

Cancer is a complex genetic disease that affects millions of people in the world. It is one of the leading causes of death worldwide, with about ten ...

Read more

Researchers created a detailed map of the placenta during labor. By studying how maternal and fetal cells communicate, they discovered signals in the...

Read more

A recent paper published in Nature Medicine (1) aimed to identify genes and genomic biomarkers which can better predict outcomes and personalized the...

Read more

In honor of the international day of women and girls in science, we interviewed one of our very own, Dr. Evelina Papaioannou. Dr. Evelina Pa...

Read more

Aneuploidies, such as translocations, whole or segmental chromosomal duplications, and deletions, are examples of chromosomal abnormalities that are ...

Read more

Here you can read the winning essays from the first, annual DNA essay competition on the subject of "How unfolding the DNA code can help with precisi...

Read more

Introduction Our voices are as unique as our fingerprints! Although there are people whose voices might sound alike, there are no two voices exact...

Read more

Not everyone likes winter. For people who do not enjoy the cold weather, or having to put on a thick coat to go outside, a winter can be a source of ...

Read more